💉 The Morning Dose #2: Alzheimer’s, Alcohol Abuse, and Pain Treatment
Welcome to The Morning Dose, July 4th recovery edition.
Your morning update on all things peptides, SARMS, TRT, and everything else that the media won’t tell you.
In this week’s edition…
New peptide may treat Alzheimer’s
Could semaglutide reduce alcohol use?
Peptides may become the future of pain medication
Let’s inject this.
New Peptide May Treat Alzheimer’s
Alzheimer’s Disease was first diagnosed in 1906, which means scientists have spent over 100 years trying to understand this devastating disease, as well as find a cure.
Alzheimer’s is the most common form of dementia, and the main symptoms are memory loss and confusion early on, with later stages progressing to loss of bodily control, inability to recognize loved ones, and loss of independence.
This is a truly sad disease, and many of us have loved ones who’ve been affected.
Fortunately, treatment may finally be on the way.
In a study funded by the National Institutes of Health, researchers at the Massachusetts Institute of Health have found a way to block the CDK5 enzyme, which is typically overactive in the brains of Alzheimer’s patients.
When mice were treated with this peptide, they showed dramatic reductions in neurodegeneration and DNA damage in the brain, as well as an improved ability to learn new tasks.
We may still be years away from human trials, but this is an incredibly promising discovery, and one worth keeping an eye on.
Could Semaglutide reduce alcohol use?
When it comes to reducing alcohol, some people have no problem cutting out their weekly drinking…
Others, not so much.
According to a 2021 survey, 29.5 million people ages 12 and up had Alcohol Use Disorder (AUD) in the previous year.
That’s a LOT of people who really struggle to regulate their drinking habits.
hen willpower isn’t enough, sometimes we need pharmaceutical interventions to help people who struggle with alcohol.
Semaglutide, the weight loss peptide, may become the future of alcohol treatment.
A new study published in eBioMedicine showed that semaglutide reduced alcohol intake in rats with a drinking problem, as well as prevented relapse drinking.
Most of us think of semaglutide as a weight loss drug–and those rats did lose weight, but the ability to reduce alcohol intake may be an even more powerful use.
As with the Alzheimer’s study, this study was done on rats, not humans…
But fortunately, semaglutide is extremely popular right now and approved for human use. I have to imagine that further research on this wonder peptide and alcohol intake in humans is right around the corner.
Peptides: The Future of Pain Medication?
The Opioid Epidemic reared its head in the early stages of Covid-19 lockdowns, with drug overdose deaths increasing by 30.6% in the United States in 2020.
Some states saw even higher rates, with Mississippi recording a 56% increase in drug overdoses.
Yes, opioids are powerful tools for pain relief, but they’re also very easy to become addicted to, and as we’ve seen, this addiction can quickly lead to a tragic overdose.
All of this may soon become a thing of the past.
Researchers have begun to study opioid receptors, and specifically, which peptides seem to act on these receptors.
The goal? Scientists want to find a peptide that can relieve pain the same way opioids do, without the dangerous side effects, altered mental states, and addictive properties.
In all likelihood, we’re still a long way away from using peptides to relieve pain (aside from faster injury healing with BPC-157 or TB-500), but it’s amazing to see that money is finally being spent to find an alternative to opioids.
We’ve recently completed our brand-new, FREE Peptides course. This comprehensive email course will teach you everything you need to know about how to safely use research peptides for muscle building, fat loss, hormone optimization, and more.
Click here to sign up for the free course.
-The Morning Dose
Want to stop receiving The Morning Dose? No problem – click here, and we won’t send you any more editions of The Morning Dose. You’ll continue to receive our other messages.